Royalty Pharma posts Q3 2026 receipts up 9% and lifts full‑year outlook
Royalty Pharma reported third‑quarter 2026 portfolio receipts of $890 million, a 9% year‑over‑year increase, driven by therapies such as Tremfya and Voranigo. The company raised its full‑year 2026 portfolio receipts guidance to $3.50 billion‑$3.55 billion and recorded a $150 million non‑cash impairment charge related to pelacarsen. It also acquired royalty interests in Zoryve and Mimrylo for $100 million each and deployed $362 million of capital during the quarter.
Why it matters
The higher guidance suggests stronger cash‑flow generation for the remainder of 2026, which may support continued dividend payments and share repurchases. The $150 million impairment reduces the net income for the quarter but does not affect the cash‑flow outlook.
Key facts
- 1Portfolio receipts increased 9% to $890 million in Q3 2026. tradingview.com
- 2Full‑year 2026 portfolio receipts guidance was raised to $3.50 billion‑$3.55 billion. tradingview.com
- 3Operating income was $411 million, down from $427 million in Q3 2025. tradingview.com
- 4Royalty Pharma recorded a $150 million non‑cash impairment charge related to pelacarsen. tradingview.com
- 5The company acquired royalty interests in Zoryve and Mimrylo for $100 million each. tradingview.com
- 6Capital deployed during the quarter was $362 million, bringing YTD deployment to $1.2 billion. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.